Harold Knoll

EverZom is an exosome biotech company developing treatments for digestive tissue healing like Crohns fistula and organ regeneration like the kidney and the liver. Founded in 2019, EverZom is positioned to become the leader of exosome therapeutics, the next wave of innovation for the biotech industry. Exosomes, small vesicles secreted by cells, are increasingly recognized as potent agents for intercellular communication and play a crucial role to treat a wide range of diseases. Winner of the European EIC Accelerator Program, EVerZom aims to be the upcoming pioneer in this new field. The company has successfully developed a multi-patented platform which enables exosome sourcing, generation, loading, and formulation to create proprietary programs and establish early-stage partnerships in the field of regenerative therapy and oncology.

Rejuvenation Technologies is a longevity startup company based in Mountain View, California. To learn more, visit us at rejuvenationtech.com.

PannTheraPi is the first pharmaceutical company dedicated to the development of Pannexin 1 channel blocker drugs for the treatment of brain and nervous diseases, aiming for better efficacy and better tolerance than current drugs. PannTheraPi offers breakthrough innovation for the two main issues in development of current drugs in neurological diseases: - Innovative target adressing the root cause of the diseases - Representative non-clinical model using human brain tissues PanTheraPi generates repurposed and new chemical entities drugs.

Cinessance, the renaissance of French cinema. Cinessance is the first Video On Demand platform of French cinema, accessible anywhere in the world.

Genome editing-based therapies become the predominant technology of the 21st century with promising statements about genetic diseases treatments. Genome editing tools recently emerged but they suffer from an absence of standardization and their applications remain limited. In this context, Quidditas developed a novel genome editing platform which permits an absolute genetic recombination. Compatible with a larger scope of applications, from bioprocess improvement to genetic disorders treatment, this revolutionary technique will have a major impact in the synthetic Bio field. So “Let’s cure from the beginning!”

Téléchargez notre app et commencez à consommer de manière responsable et solidaire ! 💪

Kraken helps people own the power of their money. Founded in 2011, were one of the worlds longest-standing crypto platforms, now offering crypto, stocks, futures, staking, payments and more. Trusted by millions of institutions, professional traders, and consumers across 190+ countries. Built on the belief that everyone should own the power of their money, Kraken has been a category leader in crypto since 2011. Weve grown into a global financial platform offering crypto, stocks, futures, staking, payments and institutional infrastructure — all on a single foundation built for the future of finance. Our product lineup: — Kraken: the worlds leading hybrid investment platform, built for the future of finance from the ground up — Kraken Pro: the all-in command center that unleashes your trading potential — Krak: the next-generation money platform that turns every type of asset into usable money Proof of Reserves since 2014. Assets held 1:1. Trusted by 13M+ people, thousands of institutions, and a growing community of developers building on Kraken rails. Our mission: accelerate the global adoption of crypto so everyone can achieve financial freedom and inclusion. Risk Disclosure: https://www.kraken.com/en-ca/social-media-disclosure

Founded in France, in 2017, Mainbot offers a new way of learning with immersive training for companies, and two flagship products: Winky, the companion robot for children to learn programming with fun, and The Winkyverse, the first digital game-based learning metaverse. Delivered with two free applications, Winky allows you to discover robotics and programming through games. The "Winky Play" application puts Winky at the heart of the experience by offering fun and varied games, while the "Winky Code" application teaches children to program by taking on many challenges. Through these fun and educational games and challenges, children improve perception, memory and motor skills. The Winkyverse, supported by France 2030 (State investment program), aims to become an open platform bringing together the knowledge of everyone (individuals and companies) accessible via Academies, in the form of 3D spaces allowing learning in an interactive environment. Mainbot also supports companies in the integration of Web3 technologies (Blockchain, NFT, tokenomics, metaverse) with off-the-shelf training, ready-to-use tools and the design of customized immersive experiences to train and engage your employees. The first ready-to-use learning module intended for sales to businesses will be released at the beginning of 2024 and will be presented in the form of an introduction to sustainable development. For more information about: - The Winkyverse ® | www.winkyverse.io | (X-Twitter) @TheWinkyverse_ | (Facebook) @TheWinkyverse | (Instagram) @The_Winkyverse - Winky ® | www.heywinky.com | (X-Twitter) @winkyrobot | (YouTube/Facebook) @WinkyRobot | (Instagram) @winky_robot_fr - Mainbot ® | www.mainbot.me | (X-Twitter/Facebook) @mainbotme - Our business Web3 services and training | https://contact.mainbot.me/businessoffer3 - Our immersive training about sustainable development | https://contact.mainbot.me/mayaquest/en

EverZom is an exosome biotech company developing treatments for digestive tissue healing like Crohns fistula and organ regeneration like the kidney and the liver. Founded in 2019, EverZom is positioned to become the leader of exosome therapeutics, the next wave of innovation for the biotech industry. Exosomes, small vesicles secreted by cells, are increasingly recognized as potent agents for intercellular communication and play a crucial role to treat a wide range of diseases. Winner of the European EIC Accelerator Program, EVerZom aims to be the upcoming pioneer in this new field. The company has successfully developed a multi-patented platform which enables exosome sourcing, generation, loading, and formulation to create proprietary programs and establish early-stage partnerships in the field of regenerative therapy and oncology.

Ultrahuman is the worlds most comprehensive self-quantification platform. Ultrahuman’s products include the Ultrahuman Ring AIR–the world’s lightest sleep-tracking wearable; Ultrahuman M1–a continuous glucose monitoring platform; Ultrahuman Home–a home health device that monitors environmental markers that affect your health every day; and Blood Vision–a preventive blood testing platform with the pioneering UltraTrace™ technology. The Ultrahuman Ring AIR is the worlds lightest sleep tracking wearable that accurately measures your sleep, HRV, movement, and temperature, with insights to help you improve your health every day. The Ultrahuman M1 helps you measure the impact of food and activity on your body in real time through glucose as a biomarker. When worn together, the Ring AIR with M1 is uniquely powerful. The glucose data from the M1 in convergence with the movement, body and sleep data from Ring AIR provide deep correlations to improve your metabolic health. The Ultrahuman Home is a silent and sophisticated home health device that monitors environmental markers that affect your health every day, including exposure to artificial light, air quality, humidity, and noise levels. It’s a first for the wearable space to leverage home health data and correlate the home environment (humidity, air quality, temperature) to an individual’s lifestyle (sleep, stress). With Blood Vision, users can do more than just ascertain their current health status. The pioneering UltraTrace™ technology seamlessly correlates changes in your sleep, resting HR, HRV, and movement trends with pertinent markers in the blood.

Official Partner in the UK of Abbotts CGM consumer brand Lingo

Rejuvenation Technologies is a longevity startup company based in Mountain View, California. To learn more, visit us at rejuvenationtech.com.

PannTheraPi is the first pharmaceutical company dedicated to the development of Pannexin 1 channel blocker drugs for the treatment of brain and nervous diseases, aiming for better efficacy and better tolerance than current drugs. PannTheraPi offers breakthrough innovation for the two main issues in development of current drugs in neurological diseases: - Innovative target adressing the root cause of the diseases - Representative non-clinical model using human brain tissues PanTheraPi generates repurposed and new chemical entities drugs.